Mer­ck touts a con­fir­ma­to­ry Keytru­da win for liv­er can­cer as 'dan­gling' ac­cel­er­at­ed ap­proval saga march­es on

Ac­cel­er­at­ed ap­proval for Mer­ck’s Keytru­da in a com­mon form of liv­er can­cer looked ten­u­ous af­ter a con­fir­ma­to­ry study whiffed on two sur­vival mea­sures. But af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER